SEND NEWS ARTICLE TO FRIEND
To Email:
From Email:
News Headline
Pluristem Therapeutics is Advancing Toward Two Phase IIb Clinical Trials for Treatment of Critical Limb Ischemia and Moderate-Severe Claudication